236 related articles for article (PubMed ID: 11719428)
1. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.
Lee SB; Kim SH; Bell DW; Wahrer DC; Schiripo TA; Jorczak MM; Sgroi DC; Garber JE; Li FP; Nichols KE; Varley JM; Godwin AK; Shannon KM; Harlow E; Haber DA
Cancer Res; 2001 Nov; 61(22):8062-7. PubMed ID: 11719428
[TBL] [Abstract][Full Text] [Related]
2. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
Vahteristo P; Tamminen A; Karvinen P; Eerola H; Eklund C; Aaltonen LA; Blomqvist C; Aittomäki K; Nevanlinna H
Cancer Res; 2001 Aug; 61(15):5718-22. PubMed ID: 11479205
[TBL] [Abstract][Full Text] [Related]
3. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
4. [Li-Fraumeni syndrome: update, new data and guidelines for clinical management].
Frebourg T; Abel A; Bonaiti-Pellie C; Brugières L; Berthet P; Bressac-de Paillerets B; Chevrier A; Chompret A; Cohen-Haguenauer O; Delattre O; Feingold J; Feunteun J; Frappaz D; Fricker JP; Gesta P; Jonveaux P; Kalifa C; Lasset C; Leheup B; Limacher JM; Longy M; Nogues C; Oppenheim D; Sommelet D; Soubrier F; Stoll C; Stoppa-Lyonnet D; Tristant H
Bull Cancer; 2001 Jun; 88(6):581-7. PubMed ID: 11459705
[TBL] [Abstract][Full Text] [Related]
5. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.
Varley JM; McGown G; Thorncroft M; Santibanez-Koref MF; Kelsey AM; Tricker KJ; Evans DG; Birch JM
Cancer Res; 1997 Aug; 57(15):3245-52. PubMed ID: 9242456
[TBL] [Abstract][Full Text] [Related]
6. [Li-Fraumeni syndrome].
Tsunematsu Y
Nihon Rinsho; 2000 Jul; 58(7):1442-7. PubMed ID: 10921321
[TBL] [Abstract][Full Text] [Related]
7. Mutation analysis of the CHK2 gene in families with hereditary breast cancer.
Allinen M; Huusko P; Mäntyniemi S; Launonen V; Winqvist R
Br J Cancer; 2001 Jul; 85(2):209-12. PubMed ID: 11461078
[TBL] [Abstract][Full Text] [Related]
8. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
9. Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23.
Bachinski LL; Olufemi SE; Zhou X; Wu CC; Yip L; Shete S; Lozano G; Amos CI; Strong LC; Krahe R
Cancer Res; 2005 Jan; 65(2):427-31. PubMed ID: 15695383
[TBL] [Abstract][Full Text] [Related]
10. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
[TBL] [Abstract][Full Text] [Related]
11. Three germline mutations in the TP53 gene.
Cornelis RS; van Vliet M; van de Vijver MJ; Vasen HF; Voute PA; Top B; Khan PM; Devilee P; Cornelisse CJ
Hum Mutat; 1997; 9(2):157-63. PubMed ID: 9067756
[TBL] [Abstract][Full Text] [Related]
12. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families.
Bougeard G; Sesboüé R; Baert-Desurmont S; Vasseur S; Martin C; Tinat J; Brugières L; Chompret A; de Paillerets BB; Stoppa-Lyonnet D; Bonaïti-Pellié C; Frébourg T;
J Med Genet; 2008 Aug; 45(8):535-8. PubMed ID: 18511570
[TBL] [Abstract][Full Text] [Related]
14. Characterization of tumor-associated Chk2 mutations.
Wu X; Webster SR; Chen J
J Biol Chem; 2001 Jan; 276(4):2971-4. PubMed ID: 11053450
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel TP53 mutations in familial and sporadic cancer cases of German and Swiss origin.
Bendig I; Mohr N; Kramer F; Weber BH
Cancer Genet Cytogenet; 2004 Oct; 154(1):22-6. PubMed ID: 15381368
[TBL] [Abstract][Full Text] [Related]
16. Germ-line exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni syndrome family.
Stolzenberg MC; Brugières L; Gardes M; Dessarps-Freichey F; Chompret A; Bressac B; Lenoir G; Bonaïti-Pellié C; Lemerle J; Feunteun J
Oncogene; 1994 Oct; 9(10):2799-804. PubMed ID: 8084585
[TBL] [Abstract][Full Text] [Related]
17. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.
Birch JM; Blair V; Kelsey AM; Evans DG; Harris M; Tricker KJ; Varley JM
Oncogene; 1998 Sep; 17(9):1061-8. PubMed ID: 9764816
[TBL] [Abstract][Full Text] [Related]
18. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
[TBL] [Abstract][Full Text] [Related]
19. TP53, hChk2, and the Li-Fraumeni syndrome.
Varley J
Methods Mol Biol; 2003; 222():117-29. PubMed ID: 12710683
[TBL] [Abstract][Full Text] [Related]
20. Concomitant inactivation of p53 and Chk2 in breast cancer.
Sullivan A; Yuille M; Repellin C; Reddy A; Reelfs O; Bell A; Dunne B; Gusterson BA; Osin P; Farrell PJ; Yulug I; Evans A; Ozcelik T; Gasco M; Crook T
Oncogene; 2002 Feb; 21(9):1316-24. PubMed ID: 11857075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
